browse categories
Gerben Zijlstra
Platform Marketing Manager Continuous BioManufacturing

Scalable Technologies for Intensified Biomanufacturing


Despite their low costs, rapid deployment and flexibility, the current Single-Use facilities are limited by their output, typically 500 kg/year for a 6 x 2000 L facility at 3 g/L Fed Batch titer. This also limits their usefulness for commercial scale manufacturing of multiple midsize portfolio products. Upstream process intensification can solve this limitation. With consistent effective titers of 10 g/L and beyond, annual outputs of 1500 kg/year can be realized from Single Use facilities so they become an even more attractive option for commercial manufacturing of multiple products. To this point however, the development and scale-up of intensified upstream has been cumbersome and time consuming. 

In this presentation a platform of upstream process intensification tools and technologies are shown, that can greatly speed-up and improve process development, scale-up and commercial scale process control. 

Examples will be shown including an effective titer boost from 3 to 10 g/L in 12 days of culture, using commercially available platform tools. This includes cell line, media, process development tools and commercial scale manufacturing tools along with facility designs for intensified upstream processes.

Please register now to reserve your spot for this exciting webinar and we look forward to welcoming you to our presentation.

Presented by

Gerben Zijlstra,

Platform Marketing Manager Continuous BioManufacturing

Gerben is a regular speaker on process intensification, process integration and continuous biomanufacturing.

He received his Ph.D. from the University of Wageningen (The Netherlands) in the field of process integration in animal cell culture. 

He has worked for more than 20 years at CMO DSM Biologics and has been involved in the development of several commercial Bio-therapeutics, as well as innovation projects. He was one of the early adopters of Single Use bioreactors and is the first inventor of the Concentrated Fed-Batch - XD® technology, amongst others licensed by Amgen. Gerben was deeply involved in the scale-up and tech transfer of XD® technology to the Brisbane (Australia) site, which later received the 2014 ISPE facility of the year award for process innovations.

Subsequently, as a Consultant, Gerben has been working on several Continuous BioManufacturing projects.

Since end of 2016 he has become Platform Marketing Manager for Continuous BioManufacturing at Sartorius Stedim Biotech.

Learning objectives
  • Developing intensified and continuous bioprocesses
  • Configuring process-scale equipment for intensified and continuous bioprocessing
  • Emerging cell retention technologies
  • Role of PAT tools for continuous bioprocessing
  • Process Development Scientists
  • Process Development Managers
  • Process Engineers
  • Engineering Directors
Partners and Clients

Copyright © 2022, AstraNova Ltd. All Rights Reserved.